AI-generated summaries. Verify every claim with the cited sources before acting on them. Read our methodology

← Back to all reports

Paroxysmal Nocturnal Hemoglobinuria

Recent research efforts aimed at curing Paroxysmal Nocturnal Hemoglobinuria.

Last updated

Paroxysmal Nocturnal Hemoglobinuria

Overview

Paroxysmal nocturnal hemoglobinuria (PNH) is a rare acquired blood-stem-cell disorder. A mutation in the PIGA gene causes a clone of blood cells to lose protective surface proteins, leaving red blood cells vulnerable to destruction by the complement system, a normal part of immune defense. The disease can cause anemia, fatigue, dark urine, dangerous blood clots, kidney injury, and bone-marrow failure; its severity varies widely, including overlap with aplastic anemia. PNH consensus statement

The current standard of care is long-term complement inhibition—traditionally C5 inhibitors such as eculizumab or ravulizumab, with newer drugs acting earlier in the complement cascade—plus transfusions, anticoagulation when indicated, vaccination and infection precautions, and management of associated marrow failure. These medicines can greatly reduce hemolysis and thrombosis but do not remove the mutant stem-cell clone. Allogeneic hematopoietic stem-cell transplantation (HSCT), in which donor marrow replaces the patient’s blood-forming system, remains the only established potentially curative treatment, but its risks mean it is usually reserved for selected patients with severe marrow failure, refractory disease, or other high-risk indications. PNH consensus statement Polish multicenter HSCT analysis

Scope of Recent Research (2020–present)

Research activity since 2020 has been substantial, but it has concentrated far more on improving lifelong complement control than on directly curing PNH. The central curative questions are how to eliminate or replace the PIGA-mutant hematopoietic stem-cell clone, how to prevent the immune conditions that favor its expansion, and how to make transplantation safer; as of August 8, 2026, no PNH-specific gene-editing or gene-addition cure has entered the clinical sources reviewed here. Pathogenesis of PNH NHLBI marrow-failure research

Major Breakthroughs and Emerging Therapies

Donor stem-cell replacement remains the curative strategy. Allogeneic HSCT can eradicate the patient’s abnormal blood-forming system and establish donor-derived blood production. A 2020 multicenter Polish analysis described allogeneic HSCT as the sole potentially curative therapy for PNH and reported one-year overall survival of 88.9% in classic PNH and 85.1% in patients with bone-marrow-failure/PNH syndromes, although these outcomes came with important early transplant risks. Polish multicenter HSCT analysis Current work therefore aims less at discovering whether transplantation can cure PNH and more at improving donor availability, conditioning intensity, graft-versus-host-disease prevention, and patient selection. PNH consensus statement

Proximal complement inhibition is the major therapeutic advance, but it is not clone-eradicating. Pegcetacoplan, which blocks complement component C3 upstream of C5, improved hemoglobin more than eculizumab in the phase 3 PEGASUS trial; 85% of pegcetacoplan-treated participants avoided transfusion during the randomized period, compared with 15% receiving eculizumab. PEGASUS trial Oral factor-B inhibition with iptacopan has further demonstrated that blocking the alternative complement pathway can control both intravascular and extravascular hemolysis; the phase 3 APPLY-PNH and APPOINT-PNH studies established durable transfusion-free hematologic responses in patients previously receiving C5 inhibitors and in previously untreated patients, respectively. Iptacopan phase 3 trials These advances improve day-to-day disease control and may reduce the need for transplant in many patients, but they leave the underlying mutant clone in place. Pathogenesis of PNH

Biology-directed cure research is focused on clone selection rather than simply repairing PIGA. PNH develops through both a mutant stem cell and expansion of that clone; current evidence supports an important role for immune-mediated pressure that suppresses normal marrow while allowing glycosylphosphatidylinositol-negative, or GPI-negative, cells to persist. Pathogenesis of PNH This makes autologous gene correction unusually challenging: a successful treatment would need to restore a durable healthy stem-cell population while also overcoming the marrow environment that selected the PNH clone. In laboratory work, researchers have identified candidate growth pathways, including an RBPJ/PAF1–NOTCH signaling axis that promoted PNH-cell proliferation in cell-line experiments; this is an early mechanistic lead rather than a clinical therapy. RBPJ/PAF1 signaling study

Clinical Trials and Experimental Approaches

Recent late-stage PNH trials illustrate the contrast between highly effective disease control and cure. Apellis sponsored the phase 3 PEGASUS trial of pegcetacoplan, while Novartis sponsored the phase 3 APPLY-PNH and APPOINT-PNH studies of iptacopan; both programs improved anemia and reduced transfusion requirements, but neither was designed to eliminate the PNH stem-cell clone. PEGASUS trial Iptacopan phase 3 trials

Additional experimental approaches remain complement-focused. Alexion’s phase 3 ALPHA study tested add-on danicopan, a factor-D inhibitor, in people with clinically significant extravascular hemolysis despite eculizumab or ravulizumab, while Omeros’s phase 2 extension study is evaluating long-term treatment with OMS906. ALPHA trial protocol OMS906 phase 2 extension In parallel, the U.S. National Heart, Lung, and Blood Institute (NHLBI) continues transplant protocols that include PNH among severe marrow-failure conditions and an observational molecular-characterization study intended to clarify clonal dynamics rather than test a curative drug. NIH PNH study listing NHLBI multi-omics protocol

Methodologies and Scientific Approaches

Researchers combine flow cytometry—which measures the proportion of blood cells lacking GPI-anchored protective proteins—with clinical biomarkers such as hemoglobin, lactate dehydrogenase, bilirubin, reticulocyte count, transfusion use, thrombosis, and bone-marrow function. These measurements distinguish complement-mediated red-cell destruction from poor marrow production and help determine whether a therapy is controlling symptoms or changing the underlying clone. PNH consensus statement

For cure-oriented discovery, teams are analyzing blood and marrow samples using bulk and single-cell DNA and RNA sequencing, epigenetic profiling, proteomics, immune-cell phenotyping, and longitudinal tracking of somatic mutations. NHLBI’s current marrow-failure protocol plans to correlate these multi-omics findings with flow-cytometry results, clinical response, clonal evolution, and survival; its laboratory program also lists RNA sequencing and gene editing in PNH cells, alongside mouse models of immune-mediated marrow failure. NHLBI multi-omics protocol NHLBI marrow-failure research

Leading Institutions and Funding

The NHLBI Hematology Branch at the U.S. National Institutes of Health is a major public-sector center for PNH and related marrow-failure research, combining a large clinical program with single-cell sequencing, CRISPR-Cas9-based laboratory methods, barcoded flow cytometry, proteomics, and transplant studies. NHLBI marrow-failure research Tianjin Medical University General Hospital and the Tianjin Institute of Hematology have also contributed mechanistic work on clonal growth pathways, supported by programs including the National Natural Science Foundation of China and Tianjin municipal research funding. RBPJ/PAF1 signaling study

Industry funding has driven most late-stage drug development, including Apellis’s PEGASUS program, Novartis’s iptacopan program, Alexion’s danicopan program, and Omeros’s OMS906 development. PEGASUS trial Iptacopan phase 3 trials ALPHA trial protocol The International PNH Registry, funded by Alexion, provides a large global observational infrastructure for studying disease burden, progression, and real-world outcomes; public registry documentation identifies private-sector funding but does not provide a project-level dollar amount. International PNH Registry

Strengths, Limitations, and Challenges

The strongest achievement of the 2020–present period is that multiple complement targets now offer more complete hemolysis control, better hemoglobin responses, and more convenient oral or subcutaneous treatment options than earlier C5-only approaches. PEGASUS trial Iptacopan phase 3 trials However, these treatments are suppressive rather than curative: patients generally require continuous therapy, careful vaccination and infection-risk management, and monitoring for breakthrough hemolysis, anemia, thrombosis, and marrow failure. PNH consensus statement Iptacopan phase 3 trials

HSCT addresses the root cause by replacing the diseased hematopoietic system, but it introduces donor-matching constraints, conditioning toxicity, graft failure, infection, and acute or chronic graft-versus-host disease. Polish multicenter HSCT analysis The fundamental scientific obstacle for an autologous cure is that PNH is not simply a missing-protein disorder: researchers must address both the mutant clone and the immune or marrow-failure environment that allowed it to expand. Pathogenesis of PNH

Outlook and Future Directions

A broadly applicable, low-risk cure for PNH does not appear imminent as of August 8, 2026. The nearest established curative route remains safer, more accessible allogeneic HSCT for carefully selected patients, while the most important longer-term milestones are identification of druggable clone-survival pathways, proof that healthy autologous stem cells can persist in the PNH marrow environment, and eventual first-in-human PNH-specific cell or gene-based trials. Until then, better proximal complement inhibitors and detailed multi-omics studies should continue to improve control of disease while clarifying what a true non-transplant cure must overcome. Pathogenesis of PNH NHLBI multi-omics protocol

References

Don't see your disease? Request a report